Soloro 7 (Buprenorphine) Patch 10mg with 4

Category

Medications for the treatment of pain and related disorders.

Line

Analgesia and anesthesia.

Brand

Soloro

Molecule

Buprenorphine

Presentation

10 mg transdermal patch, packaged in a box with 4 patches.

Laboratory

Grunenthal

Indications

Soloro 7 (Buprenorphine) is indicated for the treatment of moderate to severe chronic pain in patients requiring continuous pain management and who cannot be adequately treated with non-opioid analgesics. This transdermal patch provides sustained release of buprenorphine, allowing for long-term pain control. It is particularly useful in patients with chronic diseases, such as cancer or degenerative conditions, where constant pain relief is required. Buprenorphine acts on opioid receptors in the central nervous system to reduce pain perception and improve the patient's quality of life.

Composition

Each patch contains 10 mg of buprenorphine as the active ingredient. It also contains excipients that allow for the formulation and release of the medication through the skin.

Contraindications

This medication is contraindicated in patients with known hypersensitivity to buprenorphine or any other component of the formulation. It should not be used in patients with severe respiratory problems, such as respiratory failure or severe asthma, or in those who are being treated with other opioids unless under appropriate medical supervision.

Precautions

Caution should be exercised in patients with a history of drug abuse, liver or kidney disease, and in those who are at risk of respiratory depression. Administration should be supervised by a physician, and regular monitoring of the patient's condition is recommended to adjust the dose as needed.

Storage

Store in a cool, dry place, at room temperature, away from direct light and out of reach of children. Do not use after the expiry date indicated on the package.

Prescription required.

Consult your doctor.